Co-Authors
This is a "connection" page, showing publications co-authored by NAOTO T UENO and SHARON HERMES GIORDANO.
Connection Strength
0.643
-
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112.
Score: 0.171
-
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288.
Score: 0.161
-
Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Br J Cancer. 2017 Feb 14; 116(4):509-514.
Score: 0.145
-
Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience. Breast Cancer Res Treat. 2024 Aug; 207(1):81-90.
Score: 0.061
-
Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer. 2017 Jul 01; 123(13):2422-2431.
Score: 0.036
-
Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors. PLoS One. 2017; 12(1):e0170081.
Score: 0.036
-
Has racial difference in cause-specific death improved in older patients with late-stage breast cancer? Ann Oncol. 2015 Oct; 26(10):2161-8.
Score: 0.033